Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study

被引：1
|
作者：
Villegas, Ana [1 ]
Arrizabalaga, B. [2 ]
Fernandez-lago, C. [3 ]
Mouzo, M. [4 ]
Mayans, Jr [5 ]
Gonalez-Porras, Jr [6 ]
Duarte, Rafael [7 ]
Remacha, Angel Francisco [8 ]
Luno, Elisa [9 ]
Gasquet, J. A.
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Hosp Cruces, Dept Haematol, Bilbao, Spain
[3] Hosp Juan Canalejo, Dept Haematol, La Coruna, Spain
[4] Complejo HU Vigo Xeral Cies, Dept Haematol, Vigo, Spain
[5] Hosp Arnau Vilanova, Dept Haematol, Valencia, Spain
[6] Hosp Univ Salamanca, Salamanca, Spain
[7] Hosp Duran & Reynals ICO, Bellvitge, Spain
[8] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[9] Hosp Univ Cent Asturias, Oviedo, Spain
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
10.1182/blood.V112.11.3451.3451
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1184 / 1184
页数：1
相关论文
共 50 条
  • [41] Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study
    Platzbecker, Uwe
    Germing, Ulrich
    Giagounidis, Aristoteles
    Goetze, Katharina
    Kiewe, Philipp
    Mayer, Karin Tina
    Ottmann, Oliver
    Radsak, Markus
    Wolff, Thomas
    Haase, Detlef
    Hankin, Monty
    Wilson, Dawn
    Zhang, Xiaosha
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Attie, Kenneth M.
    BLOOD, 2015, 126 (23)
  • [42] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM THE PHASE 2 PACE-MDS STUDY
    Platzbecker, U.
    Germing, U.
    Giagounidis, A.
    Goetze, K.
    Kiewe, P.
    Mayer, K.
    Ottmann, O.
    Radsak, M.
    Wolff, T.
    Haase, D.
    Hankin, M.
    Wilson, D.
    Zhang, X.
    Laadem, A.
    Sherman, M.
    Attie, K.
    HAEMATOLOGICA, 2015, 100 : 192 - 192
  • [43] A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
    U Platzbecker
    A Symeonidis
    E N Oliva
    J S Goede
    M Delforge
    J Mayer
    B Slama
    S Badre
    E Gasal
    B Mehta
    J Franklin
    Leukemia, 2017, 31 : 1944 - 1950
  • [44] A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E. N.
    Goede, J. S.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    LEUKEMIA, 2017, 31 (09) : 1944 - 1950
  • [45] Treatment of renal anemia with darbepoetin alfa -: Results of an Austrian multicentre study
    Hörl, WH
    Holzer, H
    Mayer, GJ
    WIENER KLINISCHE WOCHENSCHRIFT, 2002, 114 (23-24) : 967 - 971
  • [46] OUTCOMES OF CONTINUED AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME IN IPSS LOW AND INTERMEDIATE-1
    Moon, J. H.
    Sohn, S. K.
    Cho, Y. Y.
    Kim, Y. K.
    Kim, H. J.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. K.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Yeon, J. Deok
    HAEMATOLOGICA, 2012, 97 : 141 - 141
  • [47] The efficacy and safety of darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: Results after 53/55 weeks.
    Gabrilove, Janice
    Paquette, Ronald
    Lyons, Roger M.
    Mushtaq, Chaudhry
    Sekeres, Mikkael A.
    Lam, Hung
    Dreiling, Lyndah
    BLOOD, 2006, 108 (11) : 755A - 755A
  • [48] ACQUISITION OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH IPSS LOW AND INTERMEDIATE-1 RISK. STUDY FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROME
    Merchan, B.
    Ortega, M.
    Llamas-Poyato, M. J.
    Cortes, M.
    Arnan, M.
    Cervero, C.
    Montoro, J.
    Gimenez, T.
    Lopez, M.
    Arenillas, L.
    Valcarcel, D.
    LEUKEMIA RESEARCH, 2015, 39 : S136 - S136
  • [49] Darbepoetin alfa for the treatment of anemia in patients with myelofibrosis with myeloid metaplasia (MMM). Results from a Danish multicenter study
    Hannestad, Kathrine
    Larsen, Thomas Stauffer
    Andersen, Torbert Mourits
    Clausen, Niels Aage Toeffner
    Hansen, Per Boye
    Jensen, Bjarne Anker
    Birgens, Henrik Sverre
    Hasselbalch, Hans Carl
    BLOOD, 2007, 110 (11) : 234B - 234B
  • [50] BONE MARROW CYTOKINE CHANGES DURING TREATMENT WITH LENALIDOMIDE IN LOW AND INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITH DEL(5Q)
    Oliva, N.
    Ronco, F.
    Cuzzola, M.
    Alimena, G.
    Morabito, F.
    Spiriti, M. A. Aloe
    Galimberti, S.
    Cortelezzi, A.
    Specchia, G.
    Poloni, A.
    Ghio, R.
    Breccia, M.
    Finelli, C.
    Iacopino, P.
    D'Errigo, Mg
    Lagana, C.
    Latagliata, R.
    Nobile, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 381 - 381
12345